US prescription drug prices fall 3.1%, steepest annual drop since 1963

U.S. prescription drug prices dropped 0.8% from June to July 2026 on a seasonally adjusted basis and were 3.1% lower than a year earlier, the largest 12-month decline since March 1963, according to the Consumer Price Index ^[1][2]. Through the first seven months of 2026, the drug component of the index has not recorded a single monthly increase, and it declined in five of the six months before July ^[1].

The gauge does not measure the receipt at the pharmacy counter. It tracks payments that pharmacies collect from patients and insurers, Medicare included, and it leaves out manufacturer rebates that change hands after the sale, the Bureau of Labor Statistics told Axios ^[1][2].

Analysts offer a mix of explanations and split over which carries the most weight.

Medicare's authority to bargain over drug prices, established by the 2022 Inflation Reduction Act, produced its first set of negotiated prices in January. Those 10 products carry discounts reaching 79% below list price ^[1]. Juliette Cubanski, who directs Medicare policy research at KFF, cautioned that a single figure cannot separate the causes. "It's difficult to know in one number what's going on beneath the hood," she said, adding that no one policy change or initiative can be credited ^[2].

Market competition is the other broad driver. Dr. Benjamin Rome, a health policy researcher at Harvard Medical School, said prices fall when big-selling brands meet generic rivals, pointing to biosimilar copies of Humira for autoimmune conditions ^[2]. Vanderbilt health policy professor Stacie Dusetzina cited comparable reductions for Stelara, a biologic for chronic inflammatory disease ^[2].

GLP-1 pricing also enters the picture. Eli Lilly and Novo Nordisk reached agreements with the Trump administration that lowered cash prices for blockbuster GLP-1 drugs and widened Medicare coverage, which may have added to the downward pressure ^[1]. A separate policy cutting GLP-1 costs for certain eligible Medicare enrollees began in July, meaning the data capture just one month of it, experts told the Associated Press ^[2]. Which products and which enrollees qualify beyond that description has not been disclosed ^[2].

Officials and outside experts disagree publicly. The White House credited "most favored nation" agreements with manufacturers and TrumpRx, its discount-finder website, saying they are "delivering real relief to American families and putting patients first" ^[2]. Spokesperson Kush Desai dismissed the idea that the IRA deserves credit as "idiotic and unfounded," saying negotiated prices did not beat existing insurer discounts ^[1]. USC health economist Geoffrey Joyce said the site mostly surfaces discounts that already existed and that market forces account for much of the change, though he added: "If you were going to give policy credit, you'd have to say the IRA" ^[1].

Some claims remain unverified. The White House said TrumpRx has produced $700 million in patient savings without explaining the calculation, and Sen. Elizabeth Warren of Massachusetts challenged the number in a letter ^[2]. The most-favored-nation contracts are not public, and Dusetzina said the models that would implement that policy in federal health programs "have not affected payers in the index" ^[2].

Why it matters for patients

An index decline is not the same as a lower bill. The amount a person owes hinges on insurance status, plan design and cost sharing, and medicines without cheaper alternatives remain expensive ^[2]. Rome said a price measure like the CPI cannot capture what households experience with health care the way it does with groceries or gasoline ^[2]. Joyce put it plainly: "People don't care about what the true cost of the drug is. They just say, 'What's my copay?'" ^[1] Meanwhile, hospital and physician services continue to get more expensive ^[1], and higher health spending and federal policy shifts are lifting premiums and out-of-pocket costs for many people ^[2]. A KFF survey this spring found six in ten Americans worried about affording their medicines, the highest share since the group began asking in 2018, and four in ten reported not taking medication as prescribed in the prior year because of cost ^[1].

What happens next

Only July's sliver of the GLP-1 Medicare pricing policy appears in this data, so later CPI reports would show more of it ^[2]. The most-favored-nation demonstration models have yet to take effect and the contracts remain undisclosed ^[2]. The administration has continued the Medicare negotiations the law requires and forecasts more savings in coming years ^[2]. Whether the downward trend persists has not been reported.